SrasV1, PubMed, Corpus, bibRecord, 002B39

Detecting specific cytotoxic T lymphocytes against SARS-coronavirus with DimerX HLA-A2:Ig fusion protein.

Identifieur interne : 002B39 ( PubMed/Corpus ); précédent : 002B38; suivant : 002B40

Detecting specific cytotoxic T lymphocytes against SARS-coronavirus with DimerX HLA-A2:Ig fusion protein.

Auteurs : Yue-Dan Wang ; Wei Feng Chen

Source :

Clinical immunology (Orlando, Fla.) [ 1521-6616 ] ; 2004.

RBID : pubmed:15451471

English descriptors

KwdEn :
- Animals, Epitopes, T-Lymphocyte (immunology), Flow Cytometry, HLA-A2 Antigen (immunology), Humans, Immunoglobulins (immunology), Interferon-gamma (immunology), Iothalamic Acid (analogs & derivatives), Meglumine, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), T-Lymphocytes, Cytotoxic (immunology), Viral Fusion Proteins.
MESH :
- chemical , analogs & derivatives : Iothalamic Acid.
- chemical , immunology : Epitopes, T-Lymphocyte, HLA-A2 Antigen, Immunoglobulins, Interferon-gamma.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, T-Lymphocytes, Cytotoxic.
- Animals, Flow Cytometry, Humans, Meglumine, Viral Fusion Proteins.

Abstract

To assess specific cytotoxic T lymphocytes (CTLs) against Severe acute respiratory syndrome (SARS)-coronavirus, a modified DimerX flow cytometry assay was performed with peripheral blood mononuclear cell (PBMC) from HLA-A2+ SARS-recovered donors at different time points post disease. CD8+DimerX-S1203+ CTLs were detected in the PBMC from these donors up to 3 months after recovery. The percentages of CD8+DimerX-S1203+ cells paralleled the numbers of interferon-gamma-positive spots in an ELISPOT assay using the same antigenic peptide. In conclusion, DimerX-based flow cytometry staining may prove to be a real-time method to screen for CTL directed at epitopes from a newly identified virus.

DOI: 10.1016/j.clim.2004.07.004
PubMed: 15451471

Links to Exploration step

pubmed:15451471

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Detecting specific cytotoxic T lymphocytes against SARS-coronavirus with DimerX HLA-A2:Ig fusion protein.</title>
<author><name sortKey="Wang, Yue Dan" sort="Wang, Yue Dan" uniqKey="Wang Y" first="Yue-Dan" last="Wang">Yue-Dan Wang</name>
<affiliation><nlm:affiliation>Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100083, China. wangyuedan@hotmail.com</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Wei Feng" sort="Chen, Wei Feng" uniqKey="Chen W" first="Wei Feng" last="Chen">Wei Feng Chen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15451471</idno>
<idno type="pmid">15451471</idno>
<idno type="doi">10.1016/j.clim.2004.07.004</idno>
<idno type="wicri:Area/PubMed/Corpus">002B39</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B39</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Detecting specific cytotoxic T lymphocytes against SARS-coronavirus with DimerX HLA-A2:Ig fusion protein.</title>
<author><name sortKey="Wang, Yue Dan" sort="Wang, Yue Dan" uniqKey="Wang Y" first="Yue-Dan" last="Wang">Yue-Dan Wang</name>
<affiliation><nlm:affiliation>Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100083, China. wangyuedan@hotmail.com</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Wei Feng" sort="Chen, Wei Feng" uniqKey="Chen W" first="Wei Feng" last="Chen">Wei Feng Chen</name>
</author>
</analytic>
<series><title level="j">Clinical immunology (Orlando, Fla.)</title>
<idno type="ISSN">1521-6616</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Epitopes, T-Lymphocyte (immunology)</term>
<term>Flow Cytometry</term>
<term>HLA-A2 Antigen (immunology)</term>
<term>Humans</term>
<term>Immunoglobulins (immunology)</term>
<term>Interferon-gamma (immunology)</term>
<term>Iothalamic Acid (analogs & derivatives)</term>
<term>Meglumine</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>T-Lymphocytes, Cytotoxic (immunology)</term>
<term>Viral Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Iothalamic Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Epitopes, T-Lymphocyte</term>
<term>HLA-A2 Antigen</term>
<term>Immunoglobulins</term>
<term>Interferon-gamma</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
<term>T-Lymphocytes, Cytotoxic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Flow Cytometry</term>
<term>Humans</term>
<term>Meglumine</term>
<term>Viral Fusion Proteins</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To assess specific cytotoxic T lymphocytes (CTLs) against Severe acute respiratory syndrome (SARS)-coronavirus, a modified DimerX flow cytometry assay was performed with peripheral blood mononuclear cell (PBMC) from HLA-A2+ SARS-recovered donors at different time points post disease. CD8+DimerX-S1203+ CTLs were detected in the PBMC from these donors up to 3 months after recovery. The percentages of CD8+DimerX-S1203+ cells paralleled the numbers of interferon-gamma-positive spots in an ELISPOT assay using the same antigenic peptide. In conclusion, DimerX-based flow cytometry staining may prove to be a real-time method to screen for CTL directed at epitopes from a newly identified virus.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15451471</PMID>
<DateCompleted><Year>2004</Year>
<Month>11</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1521-6616</ISSN>
<JournalIssue CitedMedium="Print"><Volume>113</Volume>
<Issue>2</Issue>
<PubDate><Year>2004</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Clinical immunology (Orlando, Fla.)</Title>
<ISOAbbreviation>Clin. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Detecting specific cytotoxic T lymphocytes against SARS-coronavirus with DimerX HLA-A2:Ig fusion protein.</ArticleTitle>
<Pagination><MedlinePgn>151-4</MedlinePgn>
</Pagination>
<Abstract><AbstractText>To assess specific cytotoxic T lymphocytes (CTLs) against Severe acute respiratory syndrome (SARS)-coronavirus, a modified DimerX flow cytometry assay was performed with peripheral blood mononuclear cell (PBMC) from HLA-A2+ SARS-recovered donors at different time points post disease. CD8+DimerX-S1203+ CTLs were detected in the PBMC from these donors up to 3 months after recovery. The percentages of CD8+DimerX-S1203+ cells paralleled the numbers of interferon-gamma-positive spots in an ELISPOT assay using the same antigenic peptide. In conclusion, DimerX-based flow cytometry staining may prove to be a real-time method to screen for CTL directed at epitopes from a newly identified virus.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Yue-Dan</ForeName>
<Initials>YD</Initials>
<AffiliationInfo><Affiliation>Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100083, China. wangyuedan@hotmail.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Wei Feng</ForeName>
<Initials>WF</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Immunol</MedlineTA>
<NlmUniqueID>100883537</NlmUniqueID>
<ISSNLinking>1521-6616</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015789">HLA-A2 Antigen</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014760">Viral Fusion Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>16CHD79MIX</RegistryNumber>
<NameOfSubstance UI="D007483">Iothalamic Acid</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2303MD51O1</RegistryNumber>
<NameOfSubstance UI="C025504">iocarmate meglumine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6HG8UB2MUY</RegistryNumber>
<NameOfSubstance UI="D008536">Meglumine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015789" MajorTopicYN="N">HLA-A2 Antigen</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007483" MajorTopicYN="N">Iothalamic Acid</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008536" MajorTopicYN="Y">Meglumine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014760" MajorTopicYN="Y">Viral Fusion Proteins</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year>
<Month>06</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2004</Year>
<Month>07</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>9</Month>
<Day>29</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>12</Month>
<Day>16</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>9</Month>
<Day>29</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15451471</ArticleId>
<ArticleId IdType="doi">10.1016/j.clim.2004.07.004</ArticleId>
<ArticleId IdType="pii">S1521-6616(04)00211-6</ArticleId>
<ArticleId IdType="pmc">PMC7106176</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Clin Immunol. 2004 Jul;24(4):449-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163902</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2003 Feb 1;170(3):1291-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12538688</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Beijing Da Xue Xue Bao Yi Xue Ban. 2003 May 31;35 Suppl:70-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12914223</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>JAMA. 2003 Jul 16;290(3):374-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12865379</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cancer Res. 2001 Jul 1;61(13):5145-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11431353</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunother. 2004 Jan-Feb;27(1):48-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14676633</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 1996 Oct 4;274(5284):94-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8810254</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(11):5612-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15140958</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B39 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002B39 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:15451471
   |texte=   Detecting specific cytotoxic T lymphocytes against SARS-coronavirus with DimerX HLA-A2:Ig fusion protein.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:15451471" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Detecting specific cytotoxic T lymphocytes against SARS-coronavirus with DimerX HLA-A2:Ig fusion protein.

Detecting specific cytotoxic T lymphocytes against SARS-coronavirus with DimerX HLA-A2:Ig fusion protein.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki